临床药师参与1例新型冠状病毒肺炎患者使用奈玛特韦片/利托那韦片的药学服务

Clinical Pharmacist′s Participation in the Pharmaceutical Care of a Patient with COVID-19 Treated with Nirmatrelvir Tablets/Ritonavir Tablets

目的 探讨临床药师参与1例新型冠状病毒肺炎(COVID-19)患者使用奈玛特韦片/利托那韦片的药学监护切入点。方法 描述性分析临床药师参与1例COVID-19患者优化使用新药奈玛特韦片/利托那韦片出现肝功能异常的药物治疗过程。结果 临床药师根据患者病情变化,结合文献,优化奈玛特韦片/利托那韦片服用方式为管喂,指导护士制备奈玛特韦混悬液和利托那韦混悬液,间隔5 min内给药,且与其他食物、判断奈玛特韦片/利托那韦片与瑞舒伐他汀钙片的药物相互作用,协助医师制订个体化治疗方案。患者病情好转、出院。结论 临床药师参与医疗团队进行COVID-19患者的药学监护,有助于新药奈玛特韦片/利托那韦片的合理使用,减少药品不良反应的发生。

Objective To investigate the entry point of clinical pharmacist's participation in the pharmaceutical care of a patient with COVID-19 treated with Nirmatrelvir Tablets/Ritonavir Tablets.Methods Descriptive analysis was conducted on the clinical pharmacist's participation in the treatment of a patient with COVID-19 who developed hepatic impairment by optimized use of the new drug Nirmatrelvir Tablets/Ritonavir Tablets.Results Based on changes in the patient's condition and literature review,clinical pharmacists optimized the administration method of Nirmatrelvir Tablets/Ritonavir Tablets via feeding tube,guided nurses to prepare nirmatrelvir and ritonavir suspensions,administered within 5 min intervals,and 2 h intervals with other food and drugs,identified drug-drug interactions between Nirmatrelvir Tablets/Ritonavir Tablets and Rosuvastatin Calcium Tablets,and assisted physicians in developing personalized treatment plans.The patient's condition improved and was discharged.Conclusion The participation of clinical pharmacists in the medical team for pharmaceutical care of a patient with COVID-19 is beneficial for the rational use of new drugs such as Nirmatrelvir Tablets/Ritonavir Tablets and the reduction of adverse drug reactions.